Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

NCT01093222 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Extrahepatic Bile Duct Adenocarcinoma
Gallbladder Adenocarcinoma
Gallbladder Adenocarcinoma With Squamous Metaplasia
Hilar Cholangiocarcinoma
Recurrent Extrahepatic Bile Duct Carcinoma
Recurrent Gallbladder Carcinoma
Undifferentiated Gallbladder Carcinoma
Unresectable Extrahepatic Bile Duct Carcinoma
Unresectable Gallbladder Carcinoma

Interventions

DRUG: Erlotinib Hydrochloride
DRUG: Sorafenib Tosylate

Sponsor

National Cancer Institute (NCI)